Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01453400
Other study ID # 15772
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 27, 2011
Est. completion date April 6, 2012

Study information

Verified date December 2018
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the onset of relief provided by a single, oral dose of fast release aspirin 1000 mg compared to acetaminophen 1000 mg and placebo in subjects with sore throat pain.


Recruitment information / eligibility

Status Completed
Enrollment 177
Est. completion date April 6, 2012
Est. primary completion date April 5, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy, ambulatory, male and female subjects = 18 years of age

- Presence of sore throat due to upper respiratory tract infection (URTI)

- Onset of sore throat pain within six days of the screening period

- Baseline sore throat pain intensity score = 60 mm on the Sore Throat Pain Intensity Scale

- Have a score = 5 on the Tonsillopharyngitis Assessment

- Female subjects of childbearing potential who are currently sexually active must be using a medically acceptable form of birth control for at least one month prior to screening (three months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Nuvaring, Depo-Provera, or double-barrier and have a negative pregnancy test at screening/treatment period. Female subjects of non-childbearing potential must be amenorrheic for at least two years or had a hysterectomy and/or bilateral oophorectomy.

- Understand the pain rating assessments

Exclusion Criteria:

- History of hypersensitivity to aspirin, salicylates, other nonsteroidal anti-inflammatory drugs, acetaminophen, opioid analgesics, and similar drugs

- Use of any "cold medication" (i.e. decongestants, antihistamines, expectorants, antitussives) within four hours preceding administration of the investigational product

- Use of any immediate release analgesic/antipyretic within four hours or use of any sustained release or long-acting analgesic/antipyretic within twelve hours preceding administration of the investigational product

- Consumption of alcoholic beverages, or foods and beverages containing xanthines within two hours prior to administration of the investigational product

- Use of any sore throat lozenges, sprays, cough drops, menthol-containing products within one hour preceding administration of the investigational product

- Presence of cough that causes throat discomfort

- Presence of mouth-breathing or any respiratory condition that, in the Investigator's judgment, could compromise breathing

- Evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies for which aspirin or acetaminophen is contraindicated

- Relevant concomitant disease such as medically uncontrolled asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than fifty percent obstruction

- History of gastrointestinal bleeding or perforation related to previous non-steroidal anti-inflammatory therapy.

- Current or past history of a bleeding disorder

- Self reported alcoholism or drug abuse within two years prior to screening or routine consumption of three or more alcohol containing beverages per day

- Habituation to analgesic drugs or tranquilizers (i.e., routine use of five or more times per week for greater than three weeks)

- Acute illness, local infection, or disease (other than URTI with pharyngeal infection) that can interfere with the conduct of the study

- Current use of blood thinning (anticoagulant), low dose aspirin, or steroid drug

- Has initiated treatment for depression within the past thirty days

- Females who are pregnant or lactating

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo
Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
Acetaminophen + placebo
Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
Placebo
Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to meaningful pain relief from the Sore Throat Pain Intensity Scale (STPIS) 100 mm visual analog scale Up to two hours
Secondary Global assessment of the investigational product as a pain reliever by grading from 0 to 4 (from poor to excellent) Two hours postdose or immediately before the intake of rescue medication
Secondary Time to first perceptible relief (defined as the time when the subject presses the first stopwatch) Up to two hours
Secondary Time weighted sum of pain intensity differences (PID) scores over first hour Up to one hour
Secondary Time weighted sum of pain intensity differences (PID) scores over 2 hours Up to two hours
Secondary Percentage difference from baseline Sore Throat Pain Intensity Scale (STPIS) to STPIS at time of meaningful relief Up to two hours
See also
  Status Clinical Trial Phase
Completed NCT04016051 - Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections Phase 3
Recruiting NCT01681667 - Tablet vs. Liquid Suspension Ibuprofen in the Relief of Pain Phase 4
Completed NCT00527852 - Assessment of Flocked Swabs for the Identification of Group A Streptococcal Pharyngitis N/A
Completed NCT02178293 - Ketoprofen Lysine Salt as Mouthwash in Acute Phlogosis of the Pharyngeal Cavity Versus Benzidamine Hydrochloride Phase 4
Active, not recruiting NCT05127161 - Broad Implementation of Outpatient Stewardship N/A
Withdrawn NCT02535962 - Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Phase 2
Not yet recruiting NCT02252419 - Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat N/A
Completed NCT00798018 - Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena N/A
Completed NCT00535093 - An Assessment of Rapid Streptococcal Tests in Community Clinics in Israel N/A
Completed NCT00148499 - Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis Phase 3
Completed NCT00095368 - APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat Phase 3
Recruiting NCT06027593 - Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions N/A
Recruiting NCT03720301 - The Use of Osteopathic Medical Manipulation to Decrease the Incidence and Severity of Post-Operative Sore Throat N/A
Completed NCT01361399 - Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold Phase 3
Completed NCT01398696 - Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour Phase 4
Completed NCT01048866 - A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis Phase 3
Completed NCT01049334 - A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis Phase 3
Completed NCT00547391 - Recurrent Throat Infections and Tonsillectomy Phase 4
Completed NCT00242281 - APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat Phase 3
Completed NCT01465009 - Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold Phase 4